Literature DB >> 32823274

Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy.

Rajesh T Gandhi1, Joshua C Cyktor2, Ronald J Bosch3, Hanna Mar3, Gregory M Laird4, Albine Martin4, Ann C Collier5, Sharon A Riddler2,6, Bernard J Macatangay2,6, Charles R Rinaldo6,7, Joseph J Eron8, Janet D Siliciano9, Deborah K McMahon2,6, John W Mellors2.   

Abstract

BACKGROUND: HIV-1 proviruses persist in people on antiretroviral therapy (ART) but most are defective and do not constitute a replication-competent reservoir. The decay of infected cells carrying intact compared with defective HIV-1 proviruses has not been well defined in people on ART.
METHODS: We separately quantified intact and defective proviruses, residual plasma viremia, and markers of inflammation and activation in people on long-term ART.
RESULTS: Among 40 participants tested longitudinally from a median of 7.1 years to 12 years after ART initiation, intact provirus levels declined significantly over time (median half-life, 7.1 years; 95% confidence interval [CI], 3.9-18), whereas defective provirus levels did not decrease. The median half-life of total HIV-1 DNA was 41.6 years (95% CI, 13.6-75). The proportion of all proviruses that were intact diminished over time on ART, from about 10% at the first on-ART time point to about 5% at the last. Intact provirus levels on ART correlated with total HIV-1 DNA and residual plasma viremia, but there was no evidence for associations between intact provirus levels and inflammation or immune activation.
CONCLUSIONS: Cells containing intact, replication-competent proviruses are selectively lost during suppressive ART. Defining the mechanisms involved should inform strategies to accelerate HIV-1 reservoir depletion.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HIV proviruses; HIV reservoirs; immune activation; inflammation; residual viremia

Mesh:

Substances:

Year:  2021        PMID: 32823274      PMCID: PMC7857155          DOI: 10.1093/infdis/jiaa532

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   7.759


  28 in total

1.  Defective HIV-1 proviruses produce novel protein-coding RNA species in HIV-infected patients on combination antiretroviral therapy.

Authors:  Hiromi Imamichi; Robin L Dewar; Joseph W Adelsberger; Catherine A Rehm; Una O'Doherty; Ellen E Paxinos; Anthony S Fauci; H Clifford Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

2.  Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape.

Authors:  Ross A Pollack; R Brad Jones; Mihaela Pertea; Katherine M Bruner; Alyssa R Martin; Allison S Thomas; Adam A Capoferri; Subul A Beg; Szu-Han Huang; Sara Karandish; Haiping Hao; Eitan Halper-Stromberg; Patrick C Yong; Colin Kovacs; Erika Benko; Robert F Siliciano; Ya-Chi Ho
Journal:  Cell Host Microbe       Date:  2017-04-12       Impact factor: 21.023

Review 3.  The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies.

Authors:  Lillian B Cohn; Nicolas Chomont; Steven G Deeks
Journal:  Cell Host Microbe       Date:  2020-04-08       Impact factor: 21.023

4.  Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells.

Authors:  Szu-Han Huang; Yanqin Ren; Allison S Thomas; Dora Chan; Stefanie Mueller; Adam R Ward; Shabnum Patel; Catherine M Bollard; Conrad Russell Cruz; Sara Karandish; Ronald Truong; Amanda B Macedo; Alberto Bosque; Colin Kovacs; Erika Benko; Alicja Piechocka-Trocha; Hing Wong; Emily Jeng; Douglas F Nixon; Ya-Chi Ho; Robert F Siliciano; Bruce D Walker; R Brad Jones
Journal:  J Clin Invest       Date:  2018-01-22       Impact factor: 14.808

5.  Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy.

Authors:  Anthony R Cillo; David Vagratian; Margaret A Bedison; Elizabeth M Anderson; Mary F Kearney; Elizabeth Fyne; Dianna Koontz; John M Coffin; Michael Piatak; John W Mellors
Journal:  J Clin Microbiol       Date:  2014-09-03       Impact factor: 5.948

6.  Differential decay of intact and defective proviral DNA in HIV-1-infected individuals on suppressive antiretroviral therapy.

Authors:  Michael J Peluso; Peter Bacchetti; Kristen D Ritter; Subul Beg; Jun Lai; Jeffrey N Martin; Peter W Hunt; Timothy J Henrich; Janet D Siliciano; Robert F Siliciano; Gregory M Laird; Steven G Deeks
Journal:  JCI Insight       Date:  2020-02-27

Review 7.  Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir.

Authors:  Zheng Wang; Francesco R Simonetti; Robert F Siliciano; Gregory M Laird
Journal:  Retrovirology       Date:  2018-02-13       Impact factor: 4.602

8.  Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics.

Authors:  Nina N Hosmane; Kyungyoon J Kwon; Katherine M Bruner; Adam A Capoferri; Subul Beg; Daniel I S Rosenbloom; Brandon F Keele; Ya-Chi Ho; Janet D Siliciano; Robert F Siliciano
Journal:  J Exp Med       Date:  2017-03-24       Impact factor: 14.307

9.  HIV-1 DNA sequence diversity and evolution during acute subtype C infection.

Authors:  Guinevere Q Lee; Kavidha Reddy; Kevin B Einkauf; Kamini Gounder; Joshua M Chevalier; Krista L Dong; Bruce D Walker; Xu G Yu; Thumbi Ndung'u; Mathias Lichterfeld
Journal:  Nat Commun       Date:  2019-06-21       Impact factor: 14.919

Review 10.  The role of integration and clonal expansion in HIV infection: live long and prosper.

Authors:  Elizabeth M Anderson; Frank Maldarelli
Journal:  Retrovirology       Date:  2018-10-23       Impact factor: 4.602

View more
  25 in total

1.  Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy.

Authors:  Shane D Falcinelli; Kayla W Kilpatrick; Jenna Read; Ross Murtagh; Brigitte Allard; Simon Ghofrani; Jennifer Kirchherr; Katherine S James; Erin Stuelke; Caroline Baker; JoAnn D Kuruc; Joseph J Eron; Michael G Hudgens; Cynthia L Gay; David M Margolis; Nancie M Archin
Journal:  J Infect Dis       Date:  2021-07-02       Impact factor: 5.226

2.  Measuring the Haystack's Needles.

Authors:  David M Margolis
Journal:  J Infect Dis       Date:  2021-02-03       Impact factor: 5.226

3.  Antigen-driven clonal selection shapes the persistence of HIV-1-infected CD4+ T cells in vivo.

Authors:  Francesco R Simonetti; Hao Zhang; Garshasb P Soroosh; Jiayi Duan; Kyle Rhodehouse; Alison L Hill; Subul A Beg; Kevin McCormick; Hayley E Raymond; Christopher L Nobles; John K Everett; Kyungyoon J Kwon; Jennifer A White; Jun Lai; Joseph B Margolick; Rebecca Hoh; Steven G Deeks; Frederic D Bushman; Janet D Siliciano; Robert F Siliciano
Journal:  J Clin Invest       Date:  2021-02-01       Impact factor: 14.808

4.  Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1.

Authors:  Bingfeng Liu; Wanying Zhang; Baijin Xia; Shuliang Jing; Yingying Du; Fan Zou; Rong Li; Lijuan Lu; Shaozhen Chen; Yonghong Li; Qifei Hu; Yingtong Lin; Yiwen Zhang; Zhangping He; Xu Zhang; Xiejie Chen; Tao Peng; Xiaoping Tang; Weiping Cai; Ting Pan; Linghua Li; Hui Zhang
Journal:  J Clin Invest       Date:  2021-10-01       Impact factor: 14.808

5.  Single center, open label dose escalating trial evaluating once weekly oral ixazomib in ART-suppressed, HIV positive adults and effects on HIV reservoir size in vivo.

Authors:  Nathan W Cummins; Jason Baker; Rana Chakraborty; Patrick G Dean; Enrique Garcia-Rivera; Ashton Krogman; Shaji Kumar; Yury V Kuzmichev; Gregory M Laird; Alan Landay; Mathias Lichterfeld; Maryam Mahmood; Jeffrey Martinson; Mark Maynes; Sekar Natesampillai; Vincent Rajkumar; Yelizaveta Rassadkina; Kristen D Ritter; Christina G Rivera; Stacey A Rizza; Krupa Subramanian; Aaron J Tande; Elizabeth R Wonderlich; Jennifer A Whitaker; John Zeuli; Andrew D Badley
Journal:  EClinicalMedicine       Date:  2021-11-29

6.  Intact HIV Proviruses Persist in the Brain Despite Viral Suppression with ART.

Authors:  Catherine R Cochrane; Thomas A Angelovich; Michael Roche; Melissa J Churchill; Sarah J Byrnes; Emily Waring; Aleks C Guanizo; Gemma S Trollope; Jingling Zhou; Judith Vue; Lachlan Senior; Emma Wanicek; Janna Jamal Eddine; Matthew J Gartner; Trisha A Jenkins; Paul R Gorry; Bruce J Brew; Sharon R Lewin; Jacob D Estes
Journal:  Ann Neurol       Date:  2022-08-09       Impact factor: 11.274

Review 7.  An ordeal that does not heal: understanding barriers to a cure for HIV-1 infection.

Authors:  Mathias Lichterfeld; Ce Gao; Xu G Yu
Journal:  Trends Immunol       Date:  2022-08       Impact factor: 19.709

Review 8.  HIV DNA Sequencing to Detect Archived Antiretroviral Drug Resistance.

Authors:  Anna Maria Geretti; Jose Luis Blanco; Anne Genevieve Marcelin; Carlo Federico Perno; Hans Jurgen Stellbrink; Dan Turner; Tuba Zengin
Journal:  Infect Dis Ther       Date:  2022-08-01

Review 9.  Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure.

Authors:  Janet D Siliciano; Robert F Siliciano
Journal:  J Infect Dis       Date:  2021-02-15       Impact factor: 5.226

Review 10.  So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.

Authors:  Adam J Kleinman; Ivona Pandrea; Cristian Apetrei
Journal:  Viruses       Date:  2022-01-12       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.